VPC
DRUG

Vestal Point Capital’s Bright Minds Biosciences DRUG Stock Holding History

Vestal Point Capital’s Portfolio DRUG Stock Details DRUG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$35.9M Buy
+492,319
New +$39.6M 1% 36

Other funds holding DRUG

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Vestal Point Capital's DRUG Position: Q1 2026 in Review

Vestal Point Capital opened a new position in Bright Minds Biosciences (DRUG) in Q1 2026: 492,319 shares worth $35.9M. The stake represents 1% of the portfolio and ranks #36 among its holdings.

94 funds tracked by Wall St. Rank hold DRUG as of Q1 2026.

  • Vestal Point Capital held 492,319 shares of Bright Minds Biosciences worth $35.9M as of Q1 2026.
  • Bright Minds Biosciences was a new Vestal Point Capital position in Q1 2026.
  • Bright Minds Biosciences made up 1% of Vestal Point Capital's portfolio in Q1 2026, its #36 holding.
  • 94 funds tracked by Wall St. Rank held Bright Minds Biosciences as of Q1 2026.

Based on Vestal Point Capital's 13F filing for Q1 2026, filed 15 May 2026.